Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Hao, Baolan; Zhou, Jian; Shao, Shujun; Xiao, Dong

doi:10.3892/ol.2017.6270

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The physiological functions of the PLTs remained intact after treatment for at least 4 hours. PLT concentrates can be obtained by buffy coat‐derived pooled PLTs or apheresis and both products are considered equivalent blood components for patient therapy 30 . Since previous studies on acid treatment have used PLTs from pooled buffy coats or PLT‐rich plasma, 13,31 it is important also to investigate single apheresis PLTs in this context.…”

Section: Discussionmentioning

confidence: 99%

HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients

et al. 2021

View full text Add to dashboard Cite

Background Patients can form antibodies to foreign human leukocyte antigen (HLA) Class I antigens after exposure to allogeneic cells. These anti‐HLA class I antibodies can bind transfused platelets (PLTs) and mediate their destruction, thus leading to PLT refractoriness. Patients with PLT refractoriness need HLA‐matched PLTs, which require expensive HLA typing of donors, antibody analyses of patient sera and/or crossmatching. An alternative approach is to reduce PLT HLA Class I expression using a brief incubation in citric acid on ice at low pH. Methods and Materials Apheresis PLT concentrates were depleted of HLA Class I complexes by 5 minutes incubation in ice‐cold citric acid, at pH 3.0. Surface expression of HLA Class I complexes, CD62P, CD63, phosphatidylserine, and complement factor C3c was analyzed by flow cytometry. PLT functionality was tested by thromboelastography (TEG). Results Acid treatment reduced the expression of HLA Class I complexes by 71% and potential for C3c binding by 11.5‐fold compared to untreated PLTs. Acid‐treated PLTs were significantly more activated than untreated PLTs, but irrespective of this increase in steady‐state activation, CD62P and CD63 were strongly upregulated on both acid‐treated and untreated PLTs after stimulation with thrombin receptor agonist peptide. Acid treatment did not induce apoptosis over time. X‐ray irradiation did not significantly influence the expression of HLA Class I complexes, CD62P, CD63, and TEG variables on acid treated PLTs. Conclusion The relatively simple acid stripping method can be used with irradiated apheresis PLTs and may prevent transfusion‐associated HLA sensitization and overcome PLT refractoriness.

show abstract

Section: Discussionmentioning

confidence: 99%

HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…One disadvantage to the BC method is lower RBC volume and hemoglobin content in the final RBC container due to RBC loss during processing 4,5 . BEST reported RBC recovery of 79% for the BC method and 85% for PRP 4,8,9 …”

Section: Bc Methods Efficacy and Qualitymentioning

confidence: 99%

Buffy coat platelets coming to America: Are we ready?

et al. 2020

View full text Add to dashboard Cite

Background Buffy coat (BC) platelets (PLTs) have been used globally for many years. In 2004 Canadian Blood Services (CBS) made the decision to transition from PLT‐rich plasma (PRP) to BC PLTs. We reviewed the benefits and manufacture process of BC and the implementation challenges involved. Study Design and Methods A literature review was performed in the following areas: BC efficacy, donor population shifts, production and good stewardship of PLTs, logistic considerations with overnight holds, advantages of the overnight hold, the CBS experience, licensure and standards, and changes needed to produce BC PLTs in the United States. The aim was to analyze current practice and identify possible actions for blood centers and hospitals. Results Implementation of BC would offer an additional source of PLTs to address the growing elderly population and the declining apheresis donor base. Substantial logistic, operational, and financial benefits were seen when CBS transitioned to BC with overnight hold. Conclusions Buffy coat blood products are widely used throughout the world. Recent conversion from PRP to BC by CBS showed that conversion can be accomplished with planning, communication, and partnership from all stakeholders. In conclusion, BC PLTs are worth serious consideration in the United States, but regulatory barriers in the United States will need to be addressed.

show abstract

What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding

Delaney

Karam

Lieberman

et al. 2022

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

Objectives: To present consensus statements and supporting literature for plasma and platelet product variables and related laboratory testing for transfusions in general critically ill children from the Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding. Design: Systematic review and consensus conference of international, multidisciplinary experts in platelet and plasma transfusion management of critically ill children. Setting: Not applicable. Patients: Critically ill pediatric patients at risk of bleeding and receiving plasma and/or platelet transfusions. Interventions: None. Measurements and Main Results: A panel of 10 experts developed evidence-based and, when evidence was insufficient, expert-based statements for laboratory testing and blood product attributes for platelet and plasma transfusions. These statements were reviewed and ratified by the 29 Transfusion and Anemia EXpertise Initiative - Control/Avoidance of Bleeding experts. A systematic review was conducted using MEDLINE, EMBASE, and Cochrane Library databases, from inception to December 2020. Consensus was obtained using the Research and Development/University of California, Los Angeles Appropriateness Method. Results were summarized using the Grading of Recommendations Assessment, Development, and Evaluation method. We developed five expert consensus statements and two recommendations in answer to two questions: what laboratory tests and physiologic triggers should guide the decision to administer a platelet or plasma transfusion in critically ill children; and what product attributes are optimal to guide specific product selection? Conclusions: The Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding program provides some guidance and expert consensus for the laboratory and blood product attributes used for decision-making for plasma and platelet transfusions in critically ill pediatric patients.

show abstract

Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Cited by 3 publications

References 18 publications

HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients

HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients

Buffy coat platelets coming to America: Are we ready?

Contact Info

Product

Resources

About